Difference between revisions of "Part:BBa K4165144"
Line 5: | Line 5: | ||
Tau binding peptide targeting the PHF seed of Tau | Tau binding peptide targeting the PHF seed of Tau | ||
− | |||
===Usage and Biology=== | ===Usage and Biology=== | ||
+ | |||
+ | MINK is a peptide with amino acid sequence of DVQMINKKRK, it is designed to inhibit the fibrillization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derives tau aggregation. MINK can bind to PHF* in a mean that can disrupt the interface between each PHF* and consequently reduce the aggregates. Its IC50 for inhibition of tau aggregates were 22.6 μM. | ||
<!-- --> | <!-- --> | ||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
<partinfo>BBa_K4165144 SequenceAndFeatures</partinfo> | <partinfo>BBa_K4165144 SequenceAndFeatures</partinfo> | ||
+ | |||
+ | ===Dry Lab=== | ||
+ | |||
+ | <p style=" font-weight: bold; font-size:14px;"> Modeling </p> | ||
+ | MINK is modeled by AlphaFold2, Apptest, ITAsser and TrRosetta, best model obtained from Apptest | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | <html> | ||
+ | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mink.png" style="margin-left:200px;" alt="" width="300" /></p> | ||
+ | </html> | ||
+ | |||
+ | Figure 1.: Predicted 3D structure of Synthetic peptide MINK. | ||
+ | |||
+ | |||
+ | |||
+ | <p style=" font-weight: bold; font-size:13px;"> Table 1: Quality assessment parameters of MINK model. </p> | ||
+ | |||
+ | <html> | ||
+ | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mink-qa.png" style="margin-left:75px;" alt="" width="800" /></p> | ||
+ | </html> | ||
+ | |||
+ | |||
+ | ===References=== | ||
+ | 1. Reference | ||
Revision as of 18:18, 5 October 2022
MINK Peptide
Tau binding peptide targeting the PHF seed of Tau
Usage and Biology
MINK is a peptide with amino acid sequence of DVQMINKKRK, it is designed to inhibit the fibrillization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derives tau aggregation. MINK can bind to PHF* in a mean that can disrupt the interface between each PHF* and consequently reduce the aggregates. Its IC50 for inhibition of tau aggregates were 22.6 μM.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Dry Lab
Modeling
MINK is modeled by AlphaFold2, Apptest, ITAsser and TrRosetta, best model obtained from Apptest
Figure 1.: Predicted 3D structure of Synthetic peptide MINK.
Table 1: Quality assessment parameters of MINK model.
References
1. Reference